Ramos Carlos H I, Ayinde Kehinde S
Institute of Chemistry, University of Campinas UNICAMP, Campinas SP, 13083-970. Brazil.
Curr Protein Pept Sci. 2020 Nov 11. doi: 10.2174/1389203721666201111160925.
Drug reposition, or repurposing, has become a promising strategy in therapeutics due to its advantages in several aspects of drug therapy. General drug development is expensive and can take more than 10 years to go through the designing, development, and necessary approval steps. However, established drugs have already overcome these steps and thus a potential candidate may be already available decreasing the risks and costs involved. Viruses invade cells, usually provoking biochemical changes, leading to tissue damage, alteration of normal physiological condition in organisms and can even result in death. Inside the cell, the virus finds the machinery necessary for its multiplication, as for instance the protein quality control system, which involves chaperones and Hsps (heat shock proteins) that, in addition to physiological functions, help in the stabilization of viral proteins. Recently, many inhibitors of Hsp90 have been developed as therapeutic strategies against diseases such as the Hsp90 inhibitors used in anticancer therapy. Several shreds of evidence indicate that these inhibitors can also be used as therapeutic strategies against viruses. Therefore, since a drug treatment for COVID-19 is urgently needed, this review aims to discuss the potential use of Hsp90 inhibitors in the treatment of this globally threatening disease.
药物重新定位，即药物再利用，由于其在药物治疗多个方面的优势，已成为一种很有前景的治疗策略。一般的药物研发成本高昂，从设计、开发到获得必要的批准，可能需要十多年时间。然而，已上市药物已经经历了这些阶段，因此可能已有潜在的候选药物，从而降低了相关风险和成本。病毒侵入细胞，通常会引发生化变化，导致组织损伤、生物体正常生理状态改变，甚至可能导致死亡。在细胞内部，病毒利用其繁殖所需的机制，比如蛋白质质量控制系统，该系统涉及伴侣蛋白和热休克蛋白（Hsps），这些蛋白除了具有生理功能外，还有助于病毒蛋白的稳定。最近，许多Hsp90抑制剂已被开发出来作为针对某些疾病的治疗策略，比如用于抗癌治疗的Hsp90抑制剂。有几条证据表明，这些抑制剂也可作为对抗病毒的治疗策略。因此，鉴于迫切需要针对新冠病毒病的药物治疗，本综述旨在探讨Hsp90抑制剂在治疗这种全球威胁性疾病中的潜在用途。
